Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)
Sponsored by Helwan University
About this trial
Last updated 2 years ago
Study ID
120-2022
Status
Recruiting
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 9 months ago
What is this trial about?
The goal of this clinical trial is to evaluate the colchicine protective effect in patients
undergoing Percutaneous Coronary Intervention (PCI). The main question it aims to answer is:
does initiating colchicine before planned PCI will reduce post-procedural myocardial injury?
Half of the participants will receive colchicine, while the other half will receive a
placebo.
What are the participation requirements?
Inclusion Criteria
- Chronic Coronary Syndrome (CCS) participants referred for PCI.
- Acute Coronary Syndrome (ACS) participants who are medically treated or undergoing revascularization for non-culprit lesions will be included if their troponin I and hs-CRP returned back to normal baseline
Exclusion Criteria
- Acute Coronary Syndrome (ACS) participants.
- Chronic kidney disease (glomerular filltration rate <30 ml/ min).
- Participants with history of cirrhosis.
- Participants on systemic immunosuppressive or corticosteroid therapy.
- Active malignancy or infection.
- Elevated troponin I.
Locations
Location
Status
Recruiting